Zhilong Ai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zhilong Ai has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Cong Wang
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, People's Republic of China
3 shared publicationsChen Li
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China
2 shared publicationsJiaoJiao Zheng
Department of General Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China
1 shared publicationJiaojiao Zheng
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China
1 shared publicationWei Liu
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, People's Republic of China
1 shared publicationWeihui Lu
Department of General Surgery, Zhongshan Hospital (Qingpu Branch), Fudan University, Shanghai 201700, P.R. China
1 shared publication
Latest Publications
- Open Access
- 1 February 2020
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 13, 1037-1046
miR-873-5p Inhibits Cell Migration and Invasion of Papillary Thyroid Cancer via Regulation of CXCL16
Aim: Papillary thyroid cancer (PTC) is the most common type of thyroid cancer with an increasing morbidity. MicroRNAs (miRNAs) play the pivotal roles in PTC occurrence and development. The aim of this study was to investigate the biological functions of miR-873-5p and its underlying molecular mechanisms in PTC. Methods: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis was performed to detect miR-873-5p expressions in PTC tissues and cell lines. The target gene of miR-873-5p was predicted by TargetScan and confirmed by dual-luciferase reporter assay. Furthermore, cell proliferation, migration and invasion were assessed by CCK-8, wound healing assay and transwell assay, respectively. Additionally, the expressions of CXCL16, MMP1, MMP9 and MMP13 were measured by RT-qPCR and Western blot methods, and p65, Rel-B and their phosphorylation levels were examined by Western blot. Results: We found that miR-873-5p expression was downregulated in PTC tissues and cell lines. Moreover, CXCL16 was identified as a target of miR-873-5p, and its expression was upregulated in PTC tissues and cells at both mRNA and protein levels. Functionally, overexpression of miR-873-5p inhibited PTC cell proliferation, migration and invasion, while co-transfection of CXCL16 overexpression plasmid reversed the anti-tumor behaviors induced by miR-873-5p. In addition, miR-873-5p overexpression suppressed the phosphorylation of p65 and Rel-B, and decreased the mRNA and protein expression of MMP1, MMP9 and MMP13, while overexpression of CXCL16 partially abrogated the effects of miR-873-5p. Conclusion: MiR-873-5p functions as a tumor suppressor in PTC by inhibiting the proliferation, migration and invasion of the PTC cells via targeting CXCL16. These findings might provide a potential novel target for the therapy of PTC.
- 1 February 2020
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 13, 1037-1046
Open AccessmiR-873-5p Inhibits Cell Migration and Invasion of Papillary Thyroid Cancer via Regulation of CXCL16
Aim: Papillary thyroid cancer (PTC) is the most common type of thyroid cancer with an increasing morbidity. MicroRNAs (miRNAs) play the pivotal roles in PTC occurrence and development. The aim of this study was to investigate the biological functions of miR-873-5p and its underlying molecular mechanisms in PTC. Methods: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis was performed to detect miR-873-5p expressions in PTC tissues and cell lines. The target gene of miR-873-5p was predicted by TargetScan and confirmed by dual-luciferase reporter assay. Furthermore, cell proliferation, migration and invasion were assessed by CCK-8, wound healing assay and transwell assay, respectively. Additionally, the expressions of CXCL16, MMP1, MMP9 and MMP13 were measured by RT-qPCR and Western blot methods, and p65, Rel-B and their phosphorylation levels were examined by Western blot. Results: We found that miR-873-5p expression was downregulated in PTC tissues and cell lines. Moreover, CXCL16 was identified as a target of miR-873-5p, and its expression was upregulated in PTC tissues and cells at both mRNA and protein levels. Functionally, overexpression of miR-873-5p inhibited PTC cell proliferation, migration and invasion, while co-transfection of CXCL16 overexpression plasmid reversed the anti-tumor behaviors induced by miR-873-5p. In addition, miR-873-5p overexpression suppressed the phosphorylation of p65 and Rel-B, and decreased the mRNA and protein expression of MMP1, MMP9 and MMP13, while overexpression of CXCL16 partially abrogated the effects of miR-873-5p. Conclusion: MiR-873-5p functions as a tumor suppressor in PTC by inhibiting the proliferation, migration and invasion of the PTC cells via targeting CXCL16. These findings might provide a potential novel target for the therapy of PTC.
- Open Access
- 6 May 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (23) , 34918-34929
Quantitative assessment of preoperative serum thyrotropin level and thyroid cancer
Quantitative assessment of preoperative serum thyrotropin level and thyroid cancer
- 6 May 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (23) , 34918-34929
Open AccessQuantitative assessment of preoperative serum thyrotropin level and thyroid cancer
Quantitative assessment of preoperative serum thyrotropin level and thyroid cancer
- 1 January 2015
- Published by Springer Nature in Molecular Genetics and Genomics
- Vol. 290 (3) , 1125-1133
Common genetic variant on 14q13.3 contributes to thyroid cancer susceptibility: evidence based on 12 studies
Several genome-wide association studies on thyroid cancer (TC) have reported similar findings of a new susceptibility locus, 14q13.3. After that, a number of studies reported that rs944289 polymorphism at chromosome 14q13.3 has been implicated in TC risk. However, these studies have yielded inconsistent results. To investigate this inconsistency, we performed a meta-analysis of 12 studies involving a total of 7,598 TC cases, 53,613 controls, and 239 nuclear families for 14q13.3–rs944289 polymorphism to evaluate its effect on genetic susceptibility for TC. An overall random-effect per-allele OR of 1.30 (95 % CI 1.21–1.40, P < 10−5) was found for the polymorphism. Significant results were also observed for under dominant and recessive genetic models. In the subgroup analysis by ethnicity, we found similar significant results for both Caucasians (T allele: OR 1.29, 95 % CI 1.17–1.42, P < 10−5) and East Asians (T allele: OR 1.33, 95 % CI 1.18–1.49, P < 10−5). Further in stratified analyses according to study design and sample size, evidence of gene–disease association was also obtained. In addition, we found that rs944289 confers its risk, for both papillary thyroid carcinoma and follicular thyroid carcinoma when stratified by histological types of TC. Furthermore, our results on stratified analysis according to radiation exposure status showed an increased sporadic TC risk, while no associations were detected among radiation-related TCs for rs944289 polymorphism. Our result demonstrated that rs944289 polymorphism on 14q13.3 is a low penetrant risk factor for developing TC.
- 1 January 2015
- Published by Springer Nature in Molecular Genetics and Genomics
- Vol. 290 (3) , 1125-1133
Common genetic variant on 14q13.3 contributes to thyroid cancer susceptibility: evidence based on 12 studies
Several genome-wide association studies on thyroid cancer (TC) have reported similar findings of a new susceptibility locus, 14q13.3. After that, a number of studies reported that rs944289 polymorphism at chromosome 14q13.3 has been implicated in TC risk. However, these studies have yielded inconsistent results. To investigate this inconsistency, we performed a meta-analysis of 12 studies involving a total of 7,598 TC cases, 53,613 controls, and 239 nuclear families for 14q13.3–rs944289 polymorphism to evaluate its effect on genetic susceptibility for TC. An overall random-effect per-allele OR of 1.30 (95 % CI 1.21–1.40, P < 10−5) was found for the polymorphism. Significant results were also observed for under dominant and recessive genetic models. In the subgroup analysis by ethnicity, we found similar significant results for both Caucasians (T allele: OR 1.29, 95 % CI 1.17–1.42, P < 10−5) and East Asians (T allele: OR 1.33, 95 % CI 1.18–1.49, P < 10−5). Further in stratified analyses according to study design and sample size, evidence of gene–disease association was also obtained. In addition, we found that rs944289 confers its risk, for both papillary thyroid carcinoma and follicular thyroid carcinoma when stratified by histological types of TC. Furthermore, our results on stratified analysis according to radiation exposure status showed an increased sporadic TC risk, while no associations were detected among radiation-related TCs for rs944289 polymorphism. Our result demonstrated that rs944289 polymorphism on 14q13.3 is a low penetrant risk factor for developing TC.